Back to search results

Study for Metastatic Colorectal Cancer with INCA33890

This study is looking at a new treatment for metastatic colorectal cancer (cancer that has spread to other parts of the body) that is microsatellite stable (a specific genetic feature of the cancer). It combines standard chemotherapy (FOLFOX) and bevacizumab with or without an investigational drug called INCA33890. The main goal is to see if adding INCA33890 helps people live longer without their cancer getting worse (progression-free survival). You might be able to join if you are 18 or older, have stage IV colorectal cancer that can't be removed by surgery, and haven't had prior treatment for metastatic disease. The study aims to enroll about 700 participants. The current status of the study is unclear.

Study design
This is an interventional study involving approximately 700 participants. It compares standard chemotherapy and bevacizumab with or without INCA33890 or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure how long participants live without their cancer progressing for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07284849

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Recruiting
PHASE3Ages 18+InterventionalTreatment
Incyte Corporation
~700 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:INCA33890PlaceboBevacizumabFOLFOX

At a glance

Recruiting sites
90 of 254 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression-Free Survival (PFS)
Measured over Up to 3 years

Conditions

CRC (Colorectal Cancer)

Explore related trials

Colorectal CarcinomaMSI1 Gene

Where it's being run

254 sites across 55 states
Italy17
Spain17
Brazil16
Japan15
Germany14
South Korea13
Georgia11
Argentina11

Study leadership

  • Incyte Medical Monitor · STUDY_DIRECTOR · Incyte Corporation

Who to contact

Incyte Corporation Call Center (US)
[email protected]
1.855.463.3463
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Stage IV colorectal adenocarcinoma not amenable to curative resection.
No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.
Measurable disease per RECIST v1.1.
ECOG performance status of 0 or 1.
Adequate organ function determined by laboratory results.

Exclusion

MSI-H/dMMR per historical data in the medical record.
BRAF V600E mutation per historical data in the medical record.
Untreated and/or progressing CNS metastases.
History of other malignancy within 2 years.
Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
Active autoimmune disease that has required systemic treatment in the past 2 years.
Significant concurrent and/or uncontrolled medical condition.
History of organ transplant, including allogeneic stem cell transplantation.

What this trial measures

  • Progression-Free Survival (PFS)Up to 3 years

    Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or death due to any cause.